prostate treatment News
-
Radiotherapy That Could Halve Prostate Cancer Treatment Time Recommended For Use in Wales
Health Technology Wales (HTW) has published guidance recommending the routine adoption of Extreme Hypofractionated Radiotherapy (EHFRT) for the treatment of localised prostate. In the UK, prostate cancer is the most common cancer in men and in Wales, more than 2,500 men each year are diagnosed with prostate cancer. Radiotherapy is included as part of primary treatment in approximately 30% of ...
By MediWales
-
The Dutch Government Elects to Sponsor the ENFORCE Trial - A Fully Funded RCT That Includes the Nanoknife System for Prostate Treatment
We are pleased to offer congratulations to Professor Jurgen Fütterer and his team at Radboud University Medical Centre in the Netherlands, for having successfully secured €3.8 million from the Dutch National Health Care Institute and ZonMw towards the ENFORCE trial, a fully funded Randomised Controled Trial for Focal Therapy which incorporates the NanoKnife System as a treatment option ...
-
American Brachytherapy Society LDR Prostate Brachytherapy Treatment Consensus Paper Recognizes Isoray’s Cesium-131
The American Brachytherapy Society (ABS) has recognized Isoray’s Cesium-131 in its recently released new consensus statement on the subject of low dose rate (LDR) prostate brachytherapy. This marks the first time Cesium-131 has been included in ABS’s highly respected consensus guidelines. Because Cesium-131 seeds were not available as a treatment until 2004, long-term outcomes ...
By Isoray Inc.
-
Beyond Death Valley: Medtech Veteran Breathes New Life into HIFU Company
Ryan Rhodes, new CEO of EDAP USA was featured in MDDI this week. Rhodes hales from Intuitive Surgical where he helped build the DaVinci Robot brand. He compares HIFU to the early days of robotic surgery: “The HIFU market is still in its infancy, and Rhodes said it reminds him of his early days at Intuitive Surgical, when the Irvine, CA-based robotics company was focused on prostate cancer, ...
By EDAP TMS
-
C4 Imaging Announces First Prostate Cancer Treatment Utilizing Orion HDR MRI Markers
C4 Imaging LLC is pleased to announce the first prostate cancer treatment utilizing Orion, a novel medical device that’s designed to facilitate the use of MRI in improving the accuracy of treatment. The procedure was performed by Dr Peter Rossi at the Calaway Young Cancer Center in Glenwood Springs, Colorado. “We are thrilled to be first to use Orion HDR MRI Markers in the treatment ...
-
C4 Imaging Announces an Additional FDA 510(k) Clearance for its Positive-Signal MRI Marker - Sirius
C4 Imaging LLC is pleased to announce an additional US Food and Drug Administration 510(k) clearance for its Sirius MRI Marker, a novel positive-signal MRI Marker that is used during the treatment of prostate cancer with brachytherapy. This additional 510(k) clears Sirius MRI Markers to be sterilized with ethylene oxide. Previously only gamma sterilization was available; the addition of ethylene ...
-
New Clinical Trial for Treatment in Prostate Cancer Patients with Specific Genetic Biomarkers
MiraDx, in collaboration with the UCLA Jonsson Comprehensive Cancer Center, is conducting a clinical trial to validate a novel prostate cancer biomarker panel designed to help assess patients who were at a greater risk of having long-term toxicity in response to their radiation treatment, to help guide treatment decisions. Treatment can involve radiation therapy, surgery, and/or hormone ...
By MiraDx
-
C4 Imaging Announces Sirius Positive Signal MRI Marker Given FDA 510(k) Clearance for Use with Isoray’s Cesium-131 Brachytherapy Seeds to Treat Prostate Cancer
C4 Imaging LLC is pleased to announce that Isoray Medical, Inc. (NYSE American: ISR) has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the use of C4 Imaging’s Sirius positive-signal MRI (Magnetic Resonance Imaging) Markers with Isoray’s Cesium-131, brachytherapy seeds. Sirius is implanted during the treatment of prostate cancer with brachytherapy and is used ...
-
Promaxo Announces Sale of In-Office MRI to Arizona State Urological Institute
Promaxo, Inc. (“Promaxo” or the “Company”), a medical imaging, robotics, and AI technology company, announced today the sale of its in-office MRI system to Arizona State Urological Institute (“ASUI”). Promaxo’s single-sided MRI with AI based imaging system, FDA cleared for in-office use, empowers practices and hospitals to accurately and seamlessly guide ...
-
CSIRO at Australia’s biggest ICT trade show – CeBIT
CeBIT, the nation’s leading trade show for ICT industries and research organisations, is on in Sydney from 24-26 May. The CSIRO stand, staffed by experts in science, engineering and commercialisation, will feature displays of the following technology: augmented reality visualisation to enable remote delivery of complicated expert services in healthcare, education and controlling ...
-
Isoray’s Cesium-131 Featured in Presentations at American Brachytherapy Society’s Annual Conference
The growing body of information regarding Isoray, Inc.’s (NYSE American: ISR) Cesium-131 in treating prostate cancer was highlighted in two presentations at the just concluded American Brachytherapy Society’s annual conference in Denver, Colorado. During the conference, the Prostate Snap Oral I scientific session included two abstracts that were presented by The Cesium Advisory ...
By Isoray Inc.
-
Treatment of Prostatitis - What Forms of Medicines Released?
Prostatitis is a disease characterized by the presence of inflammation and/or infection localized in the prostate gland. ...
-
Study Finds Excellent Outcomes for Intermediate Risk Prostate Cancer Patients Treated with Isoray’s Cesium-131
Investigators from the University of Pittsburgh School of Medicine have published a clinical study that demonstrates excellent outcomes for localized intermediate-risk prostate cancer patients treated with Isoray’s Cesium-131 brachytherapy, commercially known as Cesium Blu. The published article on the study, Treatment of intermediate-risk prostate cancer with Cs-131: Long-term results ...
By Isoray Inc.
-
C4 Imaging Announces Sirius Positive Signal MRI Marker Given FDA 510(k) Clearance for Use with Isoray’s Cesium-131 Brachytherapy Seeds to Treat Prostate Cancer
C4 Imaging LLC is pleased to announce that Isoray Medical, Inc. (NYSE American: ISR) has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the use of C4 Imaging’s Sirius positive-signal MRI (Magnetic Resonance Imaging) Markers with Isoray’s Cesium-131, brachytherapy seeds. Sirius is implanted during the treatment of prostate cancer with brachytherapy and is used ...
By Isoray Inc.
-
Promaxo Announces Sale of In-Office MRI to Kasraeian Urology
Promaxo, Inc. (“Promaxo” or the “Company”), a medical imaging, robotics, and AI technology company, announced today the sale of its in-office MRI system to Kasraeian Urology, a Division of Florida Physician Specialists (“Kasraeian Urology”). FDA cleared for in-office use, the Company’s single-sided MRI system with AI based imaging empowers practices and ...
-
U.S. FDA accepts supplemental new drug application (sNDA) and grants priority review for darolutamide in combination with docetaxel for metastatic hormone-sensitive prostate cancer (mHSPC)
Bayer today announced the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for the oral androgen receptor inhibitor (ARi) darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). The application is being conducted under the FDA Oncology Center of ...
By Bayer AG
-
Bayer to present latest research across its advancing oncology portfolio at AACR 2023 Annual Meeting
Bayer presents first Phase 1 results from its most advanced clinical Immuno-Oncology program, aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 New preclinical data on Bayer’s DGK zeta inhibitor being featured in oral presentation in New Drugs on the Horizon session New preclinical data on mutEGFR HER2 program, currently in Phase 1, will be presented Bayer progresses novel research ...
By Bayer AG
-
Bayer raises peak sales for Nubeqa to exceed three billion euro amid positive Phase III ARASENS trial data
Raise in peak sales expectations follows presentation of positive Phase III trial ARASENS with darolutamide (Nubeqa) in metastatic hormone-sensitive prostate cancer at 2022 ASCO GU Cancers Symposium and publication in The New England Journal of Medicine on February 17, 2022 Broad development program underway with three additional ongoing or planned large clinical studies for darolutamide ...
By Bayer AG
-
Promaxo Announces Sale of In-Office MRI to Arizona Urology
Promaxo, Inc. (“Promaxo” or the “Company”), a medical imaging, robotics, and AI technology company, announced today the sale of its in-office MRI system to Arizona Urology, a comprehensive urological care center with three physician offices in the surrounding Phoenix area. Promaxo’s single-sided MRI with AI based imaging system, FDA cleared for in-office use, ...
-
Profound Medical and Akumin Enter into U.S. Multi-Center Commercial Agreement for TULSA-PRO
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced the signing of a multi-site imaging center agreement for TULSA-PRO® with Akumin Inc. (NASDAQ/TSX:AKU) (“Akumin”), a leading ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you